FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic, Hormone Receptor-positive, HER2-negative Breast Cancer By Ogkologos - February 27, 2025 383 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the TROPION-Breast01 study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Oncogenic Drivers Associated with Late Recurrence in Postmenopausal Women with ER-positive/HER2-negative... July 10, 2020 2023 ASCO Annual Meeting Research Round Up: Improving Symptom Monitoring and... September 21, 2023 EMA Recommends Extending Indications for Pembrolizumab to Patients with Advanced Biliary... December 1, 2023 Simple Hysterectomy May Expand Treatment Options for Early-Stage Cervical Cancer March 27, 2024 Load more HOT NEWS The incredible value of going public FDA Grants Accelerated Approval to Amivantamab-vmjw for Metastatic NSCLC with EGFR... Combination Chemo Helps People with Leiomyosarcoma Live Longer The Winter Solstice
